Bempedoic Acid / Ezetimibe Oral Tablet + Placebo
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cardiovascular Diseases
Conditions
Cardiovascular Diseases, NSTEMI, STEMI
Trial Timeline
Mar 1, 2022 → Dec 1, 2023
NCT ID
NCT05263778About Bempedoic Acid / Ezetimibe Oral Tablet + Placebo
Bempedoic Acid / Ezetimibe Oral Tablet + Placebo is a approved stage product being developed by Esperion Therapeutics for Cardiovascular Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT05263778. Target conditions include Cardiovascular Diseases, NSTEMI, STEMI.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05263778 | Approved | UNKNOWN |
Competing Products
20 competing products in Cardiovascular Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| Evacetrapib | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Prasugrel (CS-747) + Clopidogrel | Eli Lilly | Phase 2 | 52 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) | Daiichi Sankyo | Approved | 85 |
| Lexiscan | Astellas Pharma | Phase 2 | 52 |
| mirabegron + tamsulosin | Astellas Pharma | Phase 1 | 33 |
| TRC150094 | Torrent Pharmaceuticals | Phase 1/2 | 41 |
| Lorcaserin hydrochloride + Placebo | Eisai | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Empagliflozin + Placebos | Eli Lilly | Approved | 85 |
| Evacetrapib + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| Midazolam + AZD5718 | AstraZeneca | Phase 1 | 33 |